Osteoporosis and Cosmetic Surgery: What Bisphosphonates and Denosumab Mean for Chin, Jaw, and Nose Bone Work, Why a Prolia Shot Should Not Simply Be Skipped, Which Bone Drugs Raise Clot Risk, and Why the Fracture Most Likely to Follow a Facelift Is a Broken Hip

The patient is 63, booked for a facelift and a chin implant, and filled out the intake form carefully. Under medications they listed blood pressure pills, a statin, and vitamin D. They did not list the injection they get every six months at their internist's office, because it is a shot, not a pill, and nobody had ever called it a medication in their hearing. The injection was denosumab, sold as Prolia. The next dose fell due three weeks after surgery, and the patient had assumed, reasonably, that they should skip it while healing.

That assumption, if acted on, carries a real risk that has nothing to do with the face. Osteoporosis is not a reason to avoid cosmetic surgery. It is a reason to ask a few specific questions, because the drugs used to treat it interact with surgery in ways that most intake forms do not capture, and because the injury most likely to follow an operation in this population is not a complication at the incision. It is a fall. What follows is why osteoporosis belongs on the intake form, what the jaw risk with bone drugs actually is, what to do with each medication, how bone quality affects facial skeletal work, and how to plan a recovery that does not end in an orthopedic ward.

Why osteoporosis belongs on a cosmetic surgery intake form

The short answer: osteoporosis is common, silent, and concentrated in exactly the age group that seeks facial rejuvenation, and its treatment drugs are often left off medication lists because they are taken weekly, yearly, or by injection.

The Bone Health and Osteoporosis Foundation estimates that about 10 million Americans have osteoporosis and roughly 44 million more have low bone mass, the stage that used to be called osteopenia. The disease is diagnosed on a DXA scan, a low-dose X-ray of the hip and spine, when the bone density T-score falls to minus 2.5 or below, or clinically when someone breaks a bone from a fall at standing height or less. The foundation's figures suggest that about one in two women and up to one in four men over 50 will break a bone because of osteoporosis. The U.S. Preventive Services Task Force recommends screening for all women 65 and older, and for younger postmenopausal women with risk factors such as low body weight, smoking, a parent with a hip fracture, or long-term steroid use.

That profile overlaps heavily with cosmetic surgery. The age limit question is increasingly theoretical, and patients in their sixties and seventies now make up a meaningful share of facelift, eyelid, and neck lift consultations. Most of them are women past menopause. A substantial fraction have been told they have low bone density, and a smaller fraction are on treatment.

The medication list is where the problem starts. Alendronate is taken once a week. Risedronate can be weekly or monthly. Ibandronate can be monthly. Zoledronic acid is an intravenous infusion given once a year. Denosumab is a shot every six months. Romosozumab is a monthly injection for a year. None of these look like a daily pill, and patients routinely forget them when asked "what do you take?" A better question, and one worth answering unprompted, is "have you ever been treated for bone density, by pill, infusion, or injection, and when was the last dose?"

Two other groups belong in the conversation. The first is patients on long-term steroids for asthma, rheumatoid arthritis, inflammatory bowel disease, or other autoimmune conditions. The American College of Rheumatology's guideline on glucocorticoid-induced osteoporosis treats prednisone at 2.5 milligrams a day or more for three months or longer as a meaningful bone risk. A short perioperative course, like the dexamethasone discussed in the piece on steroids for swelling, is not. The second group is massive weight loss patients. Bariatric surgery, gastric bypass in particular, reduces calcium and vitamin D absorption and is followed by measurable bone loss, and the patient planning a lower body lift years later may have weaker bones than their age suggests. Rapid weight loss on GLP-1 drugs also appears to reduce bone density modestly, a question still being studied.

The jaw question: osteonecrosis and facial bone surgery

The short answer: the bone drugs used for osteoporosis carry a small risk of jaw osteonecrosis, a few cases per ten thousand patients at osteoporosis doses, and it matters most for operations that work on the jawbone through the mouth.

Medication-related osteonecrosis of the jaw, abbreviated MRONJ, is defined by the American Association of Oral and Maxillofacial Surgeons as exposed bone, or bone that can be probed through a fistula, in the jaw or face that persists for more than eight weeks in a patient who has taken an antiresorptive or anti-angiogenic drug and has no history of radiation to the area. Antiresorptives are the main class of osteoporosis drugs: bisphosphonates and denosumab both slow the cells that break down bone, and in doing so they also slow the remodeling the jaw relies on to heal after injury.

The scale of the risk depends heavily on dose. Cancer patients receiving high-dose zoledronic acid or denosumab to protect bone from metastases have MRONJ rates in the range of one to several percent. Osteoporosis doses are far smaller and given far less often, and the AAOMS 2022 position paper puts the risk in osteoporosis patients at a small fraction of one percent, on the order of a few cases per ten thousand. Risk rises with longer duration of treatment, particularly beyond about four years of oral bisphosphonates, and with concurrent steroids, diabetes, smoking, and poor dental health.

The typical trigger is a tooth extraction or another procedure that exposes jawbone inside the mouth, where bacteria have direct access. That is why the risk matters unevenly across cosmetic surgery. A facelift, eyelid surgery, or body contouring does not touch the jaw. Procedures that do include sliding genioplasty and chin reduction, both usually performed through an incision inside the lower lip; mandible angle and chin implants placed through the mouth and fixed with screws; jaw surgery; and cheekbone reduction, which typically combines an intraoral cut with one near the ear. Cheek implants placed through the upper gum line belong on the same list, as covered in the piece on facial implants.

Published MRONJ cases after cosmetic facial skeletal surgery are scarce, and the low baseline rate means no surgeon will have personal experience from which to estimate it. The reasonable approach borrowed from oral surgery is to treat intraoral bone work in a patient with significant antiresorptive exposure as a higher-risk version of an extraction: a dental check beforehand to clear active infection, meticulous closure of the mucosa over the bone, an antibacterial mouth rinse after surgery, and follow-up long enough to see that the incision has healed over fully. A patient with years of bisphosphonate use who wants a sliding genioplasty purely for cosmetic reasons might reasonably weigh an implant placed through an external incision under the chin, or a filler, against the intraoral route.

Drug holidays are often raised and less often helpful. Bisphosphonates bind to bone and persist in the skeleton for years, so stopping an oral bisphosphonate a few weeks before surgery does little to change the jaw's biology. AAOMS discusses holidays for higher-risk patients but acknowledges the evidence is limited, and any decision about one belongs to the prescribing physician, not the surgeon. Denosumab is different, as the next section explains: it does not bind to bone, its effect wears off within months, and stopping it carries its own danger.

Nasal bone work deserves a note. Osteotomies in rhinoplasty, including piezo rhinoplasty, are performed on the nasal bones, not the jaw, and the incisions inside the nose are a different environment from the mouth. Osteonecrosis there is not a recognized pattern. The relevant osteoporosis question in rhinoplasty is more mechanical: thinner, more brittle nasal bones in older patients can fracture less predictably, which an experienced surgeon accounts for in planning.

What to do with each bone medication around surgery

The short answer: most osteoporosis drugs can be continued or worked around with minor timing changes, but denosumab should not be delayed, raloxifene should usually be paused for clot risk, and every one of them should be on the list the anesthesiologist sees.

Oral bisphosphonates (alendronate, risedronate, ibandronate) must be taken on an empty stomach, with a full glass of water, while staying upright for 30 to 60 minutes, because they can irritate the esophagus. That ritual collides with the day of surgery, when patients fast, are sedated, and spend much of the day lying down, and with the first days of recovery, when nausea and reclining are common. The practical answer is usually to skip or shift the weekly dose so it does not land on the day of surgery or the day after, and to resume once the patient is eating normally and can sit upright. Missing one weekly dose has no meaningful effect on bone. Calcium supplements and antacids block bisphosphonate absorption and should be separated from the dose as usual.

Zoledronic acid, the yearly infusion, often causes a flu-like reaction of fever, aches, and fatigue for a day or two after the first dose. That reaction is easily confused with the fever after plastic surgery that sends patients back to the office, so it makes sense not to schedule an infusion within a couple of weeks of an operation. Because the drug's effect lasts at least a year, moving the infusion a few weeks either way does no harm.

Denosumab is where the rules change. Unlike bisphosphonates, it does not lodge in bone; it suppresses bone breakdown only as long as it is present. When a dose is missed or delayed, bone turnover rebounds sharply, bone density gained on treatment can be lost within a year, and studies of patients who stopped the drug have documented clusters of multiple spinal fractures within months. The FDA label and the major endocrine societies advise against delaying doses, and the commonly cited guidance is that the six-monthly injection should not slip by more than a few weeks. For a patient planning jaw surgery, the prescriber may choose to time the operation toward the end of a dosing interval, when the drug's effect is waning, and give the next dose once the incision has closed. For a facelift or a tummy tuck, the injection should simply be given on schedule. A patient who stops denosumab permanently for any reason should be transitioned to another drug, usually a bisphosphonate, rather than left untreated. The FDA has also added a boxed warning about severe low calcium levels in patients with advanced chronic kidney disease taking denosumab, which is another reason a calcium level belongs in the preoperative testing panel for these patients.

Raloxifene, sold as Evista, works on estrogen receptors in bone and raises the risk of venous blood clots, in the same family of concerns raised by estrogen-containing medications in the piece on birth control and hormone therapy before surgery. Its prescribing information advises stopping it at least 72 hours before and during prolonged immobilization, such as recovery from surgery, and resuming once the patient is fully mobile. For a long facial operation or any body contouring procedure, that pause belongs on the plan alongside the measures described in the piece on blood clots after plastic surgery. Menopausal hormone therapy, sometimes used partly for bone protection, follows the same clot logic.

Anabolic drugs build bone rather than merely slowing loss. Teriparatide and abaloparatide are daily injections, and most clinicians continue them through elective surgery without interruption. Romosozumab, a monthly injection given for a year, carries a boxed warning about heart attack, stroke, and cardiovascular death, and the FDA label advises against starting it in anyone who has had a heart attack or stroke in the previous year. Any patient on romosozumab should make sure the anesthesia team knows about it, and the prescriber may prefer that an elective operation wait until the twelve-month course is complete.

Calcium and vitamin D are not drugs that need stopping, but they are worth checking. Vitamin D deficiency is common, impairs muscle strength, and is easily corrected over weeks. Calcium supplements bind some oral antibiotics, including ciprofloxacin and doxycycline, so they should be separated by several hours if those are prescribed. The pieces on pre-op nutrition and the supplement stop list cover protein intake and which products to pause; calcium and vitamin D at ordinary doses are not on that list.

"

The osteoporosis drug most likely to cause harm around cosmetic surgery is not the one that touches the jaw. It is the Prolia injection a patient skips because they assume a healing body should not be given a shot, and the spine pays for it months later.

"

Bone quality, facial implants, and the aging skeleton

The short answer: osteoporosis does not appear to meaningfully slow ordinary bone healing, but thin bone holds screws less securely, and the gradual bone loss of facial aging is a separate process that rejuvenation surgery has to account for regardless of a DXA result.

One persistent worry is that bone drugs prevent fractured or cut bone from healing. Orthopedic studies of patients who break a wrist or hip while on bisphosphonates have generally found that healing proceeds without a clinically meaningful delay, though the callus can look different on X-ray. Denosumab has shown similar results in fracture trials. For the controlled bone cuts of a genioplasty or a rhinoplasty, there is no evidence that osteoporosis treatment prevents union, and the larger risks remain the familiar ones: smoking, poorly controlled diabetes, and infection.

The mechanical question is real, though. Facial implants, sliding genioplasty segments, and cheekbone reductions are held with small titanium screws and plates. In thin, porous bone, a screw grips less, and a surgeon may need longer screws, more points of fixation, or a different plate design. Older mandibles, particularly in patients who have lost teeth, can be markedly thinner along the lower border where chin and angle implants sit. A CT scan before skeletal work, already routine in many practices, shows the bone stock directly and lets the plan account for it.

Then there is the aging face. CT studies of the facial skeleton across age groups, including a frequently cited series by Shaw and colleagues, show predictable bone loss with age: the eye sockets enlarge, the bony support beneath the cheeks recedes, the opening around the nose widens, and the jaw loses height and definition. This is part of why an older face looks hollow at the temples and cheeks and why soft tissue alone cannot fully restore it. Some studies link lower systemic bone density with more facial skeletal recession, but the two processes are not interchangeable: a normal DXA does not mean the facial skeleton has not changed, and a diagnosis of osteoporosis does not mean the face has aged faster.

This matters for planning. A deep plane facelift repositions soft tissue over a skeleton that has shrunk, and the surgeon may recommend fat grafting or implants to restore lost skeletal support. Implants placed directly on bone can, over years, sink slightly into the surface beneath them, a phenomenon long described with chin implants; whether softer, older bone accelerates that is uncertain, but it is a reasonable question for an older patient weighing an implant against fat. And thinner skin over the cheekbones and jawline, discussed in the piece on skin thinning with age, makes implant edges more visible, which argues for conservative sizes.

The fall after surgery: the fracture nobody planned for

The short answer: the most serious bone injury after cosmetic surgery in an osteoporotic patient is usually a fall at home in the first days, caused by sedating medications, low blood pressure on standing, swelling, and unfamiliar equipment, and it is largely preventable with planning.

A hip fracture in an older adult is not a minor event. It typically requires surgery, months of rehabilitation, and in published series carries a substantially increased risk of death in the following year compared with peers who did not fall. Wrist and spinal fractures are more common and less dangerous but can still turn a cosmetic recovery into a medical one. The osteoporotic patient falls more easily and breaks more easily, and the first week after surgery stacks the risk factors.

Opioids, sleep aids, muscle relaxants, and antinausea drugs all cause drowsiness or unsteadiness, and many patients are on several at once. The case for opioid-sparing recovery is stronger in older patients for this reason alone, with acetaminophen and, where appropriate, anti-inflammatories doing more of the work. Blood pressure medications combined with reduced fluid intake and some blood loss can cause a drop in pressure on standing, the classic moment of a fall being the first trip to the bathroom at night. Older patients are also more prone to the confusion described in the piece on brain fog after anesthesia, which makes unsupervised nighttime walking riskier still.

The recovery itself adds hazards. After eyelid surgery or a facelift, swelling can narrow the field of vision for several days. After body contouring, compression garments, drains, and a bent posture to protect an abdominal repair change balance. Patients sleeping elevated in a recliner, as the piece on how to sleep after surgery describes, must stand up from an unusual position. Bathrooms with wet floors and low toilets are where many of these falls happen.

Most of this is fixable with ordinary preparation. A night light along the route to the bathroom, a raised toilet seat or grab bar if needed, nonslip footwear rather than socks, the removal of loose rugs and cords, and a rule that the patient sits on the edge of the bed for a minute before standing. A caregiver present at least for the first nights, as covered in the piece on the first 72 hours and recovery houses, matters more for this patient than for a younger one. Gentle walking several times a day, the same walking that prevents blood clots, also maintains strength; the piece on exercise after surgery explains how to build back up without stressing incisions.

Positioning on the operating table belongs on the list too. Osteoporotic spines and ribs tolerate less force, and a patient with a curved upper spine from old compression fractures may need extra padding and care when positioned, especially face down for back or flank procedures. Neck extension during intubation is usually modest, but a patient with known neck arthritis or spinal fractures should mention it to the anesthesiologist. These are routine adjustments for an experienced team, provided the team knows.

The honest summary

Osteoporosis rarely stands between a patient and a cosmetic operation. It changes the plan. The first change is simply disclosure: weekly pills, yearly infusions, and six-monthly shots are easy to leave off an intake form, and each one has a specific implication. Oral bisphosphonates can usually be shifted by a few days around surgery. Zoledronic acid infusions should not land in the same fortnight as the operation. Denosumab should be given on time, because skipping it to protect healing risks spinal fractures months later. Raloxifene and hormone therapy should usually be paused for clot risk. Romosozumab deserves a conversation with the prescriber before any elective date.

The jaw risk from these drugs is real but small at osteoporosis doses, a few cases per ten thousand patients, and it applies to operations that work on the jawbone through the mouth: sliding genioplasty, intraoral chin and angle implants, jaw surgery, and cheekbone reduction. For those, a dental check, careful closure, and a conversation with the prescribing physician are reasonable. A TMJ evaluation belongs in the same pre-op visit for anyone with jaw symptoms. For a facelift, eyelid surgery, or body contouring, the jaw question does not arise.

Bone drugs do not meaningfully stop bone healing. Thin bone does change how securely screws and implants hold, which a CT scan and an experienced surgeon account for. The aging facial skeleton is a separate process that shapes every rejuvenation plan, regardless of what a DXA scan shows.

The patient at the top of this piece mentioned the injection at their pre-op visit after the surgeon asked specifically about bone treatment. Their internist gave the Prolia dose on schedule, a week before surgery. The chin implant went in through a small incision under the chin rather than through the mouth. A caregiver stayed for four nights, the oxycodone prescription went largely unused, and a night light went in the hallway. Six months later, their next bone density injection was given on time, and nothing had broken in between.